Zusammenfassung
Der unwillkürliche Speichelfluss aus dem Mund ist ein häufiges Symptom bei Patienten mit ausgeprägten Schluckstörungen, das unabhängig von der Ursache der Dysphagie auftritt. Der Speichelfluss hat negative Auswirkungen auf die Lebensqualität und die Fähigkeit zur Artikulation. Die Therapie beruht im Wesentlichen auf einer Reduktion des in normaler Menge produzierten Speichels. Eingesetzt werden systemische (Anticholinergika) und nur lokal wirksame (Injektion von Botulinumtoxin) Therapieverfahren, die auch unter palliativen Aspekten für den Patienten Gewinn bringend eingesetzt werden können.
Abstract
Drooling of saliva is a clinically relevant symptom in dysphagia independently from its etiology. Sialorrhea creates relevant hygienic and psychosocial difficulties for patients and their caregivers and interferes with articulation resulting in a decrease in quality of live. The general therapeutic concept bases mainly on the reduction of the normally produced saliva using systemic anticholinergic medications or a local treatment, like the injection of botulinum toxin.
Schlüsselwörter
Hypersalivation - Sialorrhö - Dysphagie - Botulinumtoxin - Palliativmedizin
Key words
Drooling - hypersalivation - sialorrhoea - dysphagia - botulinumtoxin - palliative care
Literatur
-
1
Lucas V, Schofield L.
Treatment of drooling.
European Journal of Palliative Care.
2000;
7
5-7
-
2
Borasio G D, Voltz R.
Palliative care in amyotrophic lateral sclerosis.
J Neurol.
1997;
244, Suppl 4
S11-17
-
3
Meng N H, Wang T G, Lien I N.
Dysphagia in patients with brainstem stroke: incidence and outcome.
Am J Phys Med Rehabil.
2000;
79
170-175
-
4
Bateson M C, Gibberd F B, Wilson R S.
Salivary symptoms in Parkinson disease.
Arch Neurol.
1973;
29
274-275
-
5 Bartolome G, Buchholz D W, Hannig C, Neumann S, Prosiegel M, Schröter-Morasch H. et al .Diagnostik und Therapie neurologisch bedingter Schluckstörungen. Stuttgart; Fischer 1993
-
6
Glickman S, Deaney C N.
Treatment of relative sialorrhoea with botulinum toxin type A: description and rationale for an injection procedure with case report.
Eur J Neurol.
2001;
8
567-571
-
7
Pal P K, Calne D B, Calne S, Tsui J K.
Botulinum toxin A as treatment for drooling saliva in PD.
Neurology.
2000;
54
244-247
-
8
Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I. et al .
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis.
J Neurol Neurosurg Psychiatry.
2000;
69
121-123
-
9
Tscheng D Z.
Sialorrhea - therapeutic drug options.
Ann Pharmacother.
2002;
36
1785-1790
-
10
Blasco P A, Stansbury J C.
Glycopyrrolate treatment of chronic drooling.
Arch Pediatr Adolesc Med.
1996;
150
932-935
-
11
Bushara K O.
Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment - botulinum toxin A injections of the parotid glands.
Med Hypotheses.
1997;
48
337-339
-
12
Shaari C M, Wu B L, Biller H F, Chuang S K, Sanders I.
Botulinum toxin decreases salivation from canine submandibular glands.
Otolaryngol Head Neck Surg.
1998;
118
452-457
-
13
Mancini F, Zangaglia R, Cristina S, Sommaruga M G, Martignoni E, Nappi G. et al .
Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
Mov Disord.
2003;
18
685-688
-
14
Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C.
Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.
J Oral Maxillofac Surg.
2003;
61
454-457
-
15
Tan E K, Lo Y L, Seah A, Auchus A P.
Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis.
J Neurol Sci.
2001;
190
95-97
-
16
Porta M, Gamba M, Bertacchi G, Vaj P.
Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders.
J Neurol Neurosurg Psychiatry.
2001;
70
538-540
-
17
Ellies M, Laskawi R, Rohrbach-Volland S, Rodel R, Beuche W.
Sekretionshemmung exokriner Drüsen des Kopf-Hals-Bereiches durch Applikation von Botulinum Toxin A.
HNO.
2001;
49
807-813
-
18
Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W.
Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands.
Laryngoscope.
2002;
112
82-86
-
19
Borg M, Hirst F.
The role of radiation therapy in the management of sialorrhea.
Int J Radiat Oncol Biol Phys.
1998;
41
1113-1119
-
20
Stalpers L J, Moser E C.
Results of radiotherapy for drooling in amyotrophic lateral sclerosis.
Neurology.
2002;
58
1308
-
21
Andersen P M, Gronberg H, Franzen L, Funegard U.
External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis.
J Neurol Sci.
2001;
191
111-114
-
22
Walker M J, Chaudhuri P K, Wood D C, Das Gupta T K.
Radiation-induced parotid cancer.
Arch Surg.
1981;
116
329-331
-
23
Nunn J H.
Drooling: review of the literature and proposals for management.
J Oral Rehabil.
2000;
27
735-743
-
24
Heider A, Engels B, Hartmann-Klosterkotter U, Kress M, Niederle N.
Hypersalivation als Leitsymptom einer Meningiosis neoplastica bei hochmalignem Non-Hodgkin-Lymphom.
Dtsch Med Wochenschr.
1993;
118
19-22
-
25
Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A.
Trihexyphenidyl treatment of clozapine-induced hypersalivation.
Int Clin Psychopharmacol.
1997;
12
213-215
-
26
Calderon J, Rubin E, Sobota W L.
Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation: a preliminary report.
Int Clin Psychopharmacol.
2000;
15
49-52
-
27
Dreyfuss P, Vogel D, Walsh N.
The use of transdermal scopolamine to control drooling. A case report.
Am J Phys Med Rehabil.
1991;
70
220-222
-
28
Dunlop R, Hockley J.
Transdermal hyoscine and drooling (letter).
Palliat Med.
1990;
4
328-329
-
29
Talmi Y P, Finkelstein Y, Zohar Y, Laurian N.
Reduction of salivary flow with Scopoderm TTS.
Ann Otol Rhinol Laryngol.
1988;
97
128-130
-
30
Brodtkorb E, Wyzocka-Bakowska M M, Lillevold P E, Sandvik L, Saunte C, Hestnes A.
Transdermal scopolamine in drooling.
J Ment Defic Res.
1988;
32
233-237
-
31
Siegel L K, Klingbeil M A.
Control of drooling with transdermal scopolamine in a child with cerebral palsy.
Dev Med Child Neurol.
1991;
33
1013-1014
-
32
Lewis D W, Fontana C, Mehallick L K, Everett Y.
Transdermal scopolamine for reduction of drooling in developmentally delayed children.
Dev Med Child Neurol.
1994;
36
484-486
-
33
Hoenig J F, Merten H A, Merten B.
Medikamentöse Hemmung der Speichelsekretion nach Oropharynxtumorresektion.
Dtsch Med Wochenschr.
1992;
117
518-519
-
34
Zeppetella G.
Nebulized scopolamine in the management of oral dribbling: three case reports.
J Pain Symptom Manage.
1999;
17
293-295
-
35
Doyle J, Walker P, Bruera E.
Nebulized scopolamine.
J Pain Symptom Manage.
2000;
19
327-328
-
36
Hyson H C, Johnson A M, Jog M S.
Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study.
Mov Disord.
2002;
17
1318-1320
-
37
Mueller P R, Biswal S, Halpern E F, Kaufman J A, Lee M J.
Interventional radiologic procedures: patient anxiety, perception of pain, understanding of procedure, and satisfaction with medication - a prospective study.
Radiology.
2000;
215
684-688
-
38
Stern L M.
Preliminary study of glycopyrrolate in the management of drooling.
J Paediatr Child Health.
1997;
33
52-54
-
39
Olsen A K, Sjogren P.
Oral glycopyrrolate alleviates drooling in a patient with tongue cancer.
J Pain Symptom Manage.
1999;
18
300-302
-
40
Lucas V, Amass C.
Use of enteral glycopyrrolate in the management of drooling.
Palliat Med.
1998;
12
207-208
-
41
Neverlien P O, Sorumshagen L, Eriksen T, Grinna T, Kvalshaugen H, Lind A B.
Glycopyrrolate treatment of drooling in an adult male patient with cerebral palsy.
Clin Exp Pharmacol Physiol.
2000;
27
320-322
-
42
Rashid H, Long J D, Wadleigh R G.
Management of secretions in esophageal cancer patients with glycopyrrolate.
Ann Oncol.
1997;
8
198-199
-
43
Mier R J, Bachrach S J, Lakin R C, Barker T, Childs J, Moran M.
Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study.
Arch Pediatr Adolesc Med.
2000;
154
1214-1218
-
44
Strutt R, Fardell B, Chye R.
Nebulized glycopyrrolate for drooling in a motor neuron patient.
J Pain Symptom Manage.
2002;
23
2-3
-
45
Newall A R, Orser R, Hunt M.
The control of oral secretions in bulbar ALS/MND.
J Neurol Sci.
1996;
139, Suppl
43-44
-
46
Serrano-Duenas M.
Treatment of sialorrhea in Parkinson's disease patients with clonidine. Double-blind, comparative study with placebo.
Neurologia.
2003;
18
2-6
-
47
Fritze J, Elliger T.
Pirenzepine for clozapine-induced hypersalviation.
Lancet.
1995;
346
1034
PD Dr. Peter P. Urban
Department of Neurology · University of Mainz
Langenbeckstraße 1
55101 Mainz
Phone: + 49/6131-174473
Fax: + 49/6131-175625
Email: urban@neurologie.klinik.uni-mainz.de
